Fairvalue-Calculator Fairvalue-Calculator
EN DE

Entrada Therapeutics, Inc (TRDA) Fair Value & Analysis

Healthcare · US · Market cap $295M

Price$7.54
Fair Value$6.05
Upside-19.8%
Quality95/100
Evidence: Low Range $4.00 – $7.57

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Entrada Therapeutics, Inc (TRDA) currently trades at $7.54, while our model-based Fair Value estimate is $6.05 — implying the stock looks roughly 19.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Entrada Therapeutics, Inc (TRDA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.05 versus a price of $7.54 — about −20% (overvalued). Model-based estimate, not financial advice.
What is the fair value of TRDA?
Our 21-model fair value for Entrada Therapeutics, Inc is $6.05 (as of Jun 25, 2026), built from audited fundamentals. The current price is $7.54.
What is the quality score of TRDA?
Entrada Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.